Cephalogics Demonstrates Repeatability of Brain Imaging Results in Visual Stimulation Study
October 18 2016 - 8:00AM
Business Wire
- In recent studies, Cephalogics
demonstrated that their new, compact, non-fiber-optic-based
High-Density Diffuse Optical Tomography (HD-DOT) system is capable
of producing results consistent with PET and fMRI.
- The studies demonstrated the ability of
the Cephalogics HD-DOT system to map small visual cortex responses
to visual stimuli. These results showcased the system’s high
spatial resolution and sensitivity to changes in brain perfusion
that are significantly smaller than the changes expected in brain
injured patients.
- The results were repeatable within
healthy subjects across measurements collected over several
months.
Cephalogics today announced that it was able to demonstrate
repeatability of brain images in healthy subjects in their visual
stimulus study. This study also showed that the company’s
High-Density Diffuse Optical Tomography (HD-DOT) system is capable
of measuring and monitoring very small, focal changes in cortical
perfusion resulting from visual stimulation in healthy volunteers.
The results were consistent and repeatable across several months on
the same subjects.
Cephalogics’ non-invasive, portable brain perfusion imaging
system is being designed to provide bedside assessments and
continuous monitoring of regional brain oxygenation in patients
suffering from stroke or traumatic brain injury.
“We are very excited to demonstrate the repeatability of brain
responses measured in healthy volunteers using our HD-DOT system,”
said Chandran Seshagiri, PhD, Lead Research Scientist at
Cephalogics. “In patients at risk for different neural pathologies,
disease or injury may alter such brain responses. We believe this
technology will help enable earlier identification and intervention
in these situations.”
Retinotopic mapping of visual cortex activation has been widely
used and accepted in early evaluations of PET and fMRI due to its
ability to generate small, regional, perfusion changes. Using a
typical retinotopic stimulation experiment, the compact non-fiber
optic Cephalogics HD-DOT system demonstrated the ability to image
retinotopic visual stimuli consistent with earlier studies using
Positron Emission Tomography (PET) and functional MRI (fMRI). These
results replicated the previous work of Joseph P. Culver, PhD at
Washington University in St. Louis, who is a pioneer of HD-DOT.
“These results show the sensitivity and spatial resolution of
Cephalogics’ DOT system and its ability to perform such
measurements with high repeatability,” said Joe Culver, PhD
Professor at Washington University and Head of the Culver Optical
Imaging Lab. “These are encouraging results for the Diffuse Optical
Tomography/Imaging field and represents a step closer to
Cephalogics’ mission to generate a high-performance compact
portable DOT system.”
The changes in cortical perfusion measured by the Cephalogics
HD-DOT system in this study were significantly smaller than the
typical perfusion changes associated with brain injury patients.
Similarly, the area of cortical tissue that changes in response to
the visual stimuli used in this study was much smaller than the
spatial extent of the perfusion deficits typically expected with
brain injuries. The ability to measure perfusion changes in
cortical tissue of such small magnitude and in such focal areas
demonstrated that the Cephologics system could have the ability to
achieve the necessary sensitivity and spatial resolution for
imaging cerebral perfusion.
In addition, repeatability of the results in healthy subjects
demonstrated the utility of the device for longitudinal monitoring
of the same individual. Giving clinicians easy access to continuous
imaging and perfusion measures at the bedside can help them
identify and treat perfusion deficits in order to avoid ischemia
and its associated adverse outcomes.
“Demonstrating repeatability across multiple measurements is an
important achievement for Cephalogics,” said Jeff Caputo, General
Manager of Cephalogics. “These results further validate our efforts
to deliver an accurate brain perfusion imaging system that can be
reliably used in recurring measurements on patients.”
The results of the studies were presented last week at The
Society for functional Near Infrared Spectroscopy biennial meeting
in Paris, France on October 13-16, 2016.
For more information about Cephalogics, visit
www.cephalogics.com.
About CephalogicsCephalogics is developing a
non-invasive, portable brain perfusion imaging system that is
designed to provide clinicians with critical information for
detecting and treating perfusion deficits and avoiding ischemia in
brain-injured patients. The system is designed to “see” the brain
through hair, skin and skull, mapping oxygen saturation in the
brain and help to facilitate early interventions, improve outcomes
and reduce healthcare costs. Cephalogics’ system utilizes Diffuse
Optical Tomography (DOT) to provide bedside imaging of multiple
cerebrovascular regions within a patient’s brain. The system’s
sensors consist of compact, high-density arrays with numerous near
infrared (NIR) laser light sources and detectors to provide
hundreds of simultaneous spatially resolved measurements per
region. These measurements are processed in real time to produce
regional maps of the oxygen saturation in cerebral tissue. Each
sensor array covers a cerebrovascular area of approximately 40cm2.
Cephalogics is developing and commercializing an imaging system
based on technology invented by Dr. Joseph P. Culver, a Professor
at Washington University and a leading researcher in the field of
Diffuse Optical Tomography. More information about the company can
be found at www.cephalogics.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161018005451/en/
ArcPoint Strategic CommunicationsChristine Dunn, 617-484-1660
x101cdunn@arcpointstrategy.com
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2023 to Apr 2024